周晓阳
心内
东院CCU主任兼东院心内科副主任，主任医师，副教授，硕士生导师
东院CCU主任兼东院心内科副主任，主任医师，副教授，硕士生导师
导师介绍
| 姓名 | 周晓阳 |
| 出生年月 | 1968年10月 |
| 单位 | 武汉大学人民医院心血管内科 |
| 所属学科 | 临床医学-内科学 |
| 职务、职称及头衔 | 东院CCU主任兼东院心内科副主任，主任医师，副教授，硕士生导师 |
| xiaoyangzh@whu.edu.cn | |
| 联系方式 | 027-88041911转89025或18986033792 |
| 研究方向 | 1）高血压，2）心肌病和心力衰竭，3）心血管代谢 |
| 个人简介 |
从事心血管临床、科研、教学工作30余年，擅长于高血压、心肌病、心力衰竭的诊治及心血管急危重症的救治。2017年以来，和阜外医院合作，积极探索“互联网+医疗”对基层高血压慢病防控管理的新模式。发表论文80余篇（SCI论文50余篇）；参编专著6部（副主编2部）；参编指南/共识9部；获发明专利4项；获湖北省科技进步二等奖和三等奖各1项；主持课题4项（包括2项国家自然科学基金），参与课题20余项（包括作为子课题/分中心负责人参与国家重点研发/重大专项课题6项）。 |
| 学术任职与荣誉 |
(1)
中华预防医学会心脏病预防与控制专业委员会常委， (2) 国家心血管病专家委员会心血管代谢医学专业委员会常委， (3) 海峡两岸医药卫生交流协会高血压专业委员会常委， (4) 中国医疗保健国际交流促进会高血压分会常委， (5) 国家心血管病专业质控中心专家委员会高血压专家工作组专家， (6) STAR 心血管病学专科委员会委员， (7) 中华医学会心血管病分会高血压学组委员， (8) 中国医师协会高血压专业委员会委员， (9) 中国老年医学学会高血压分会委员， (10) 中国健康管理协会高血压防治与管理专业委员会委员, (11) 高血压达标中心认证专家委员会委员， (12) 县域慢病管理中心建设项目专家委员会委员， (13) 国家心血管病中心高血压专病医联体湖北省中心理事会副秘书长， (14) 湖北省高血压示范中心认证委员会委员， (15) 中国医疗保健国际交流促进会心血管病精准医学分会委员， (16) 武汉生物样本库有限公司伦理委员会副主任委员， (17) 《European Heart Journal 》期刊中文版高血压专刊编委, (18) 《实用心脑肺血管病》期刊编委， (19) 《Frontiers in Pharmacology》期刊客座主编 (20) 《Cardiovascular Research》特邀审稿人。 |
| 教育履历 |
1986.09-1991.06武汉大学第一临床学院临床医学专业本科生获学士学位 1995.09-1998.06武汉大学第二临床学院内科学硕士研究生获硕士学位 2001.09-2004.06北京协和医学院阜外医院心血管临床流行病学博士研究生获博士学位 |
| 工作履历 |
1991.07-1995.06华中科技大学,同济医学院附属梨园医院,住院医师 1998.07-2001.06武汉大学,中南医院,住院医师，主治医师（1999） 1999.07-2000.07中国人民解放军总医院,急诊科进修学习 2005.01-2005.06俄勒冈健康与科学大学(美国),心血管研究院,博士后研究 2005.06-2008.01辛辛那提大学(美国),心血管研究所,博士后研究 2015.11-2016.02国家心血管病中心/阜外医院，进修学习 2017.11新加坡经济管理学院，培训学习 2004.07-至今武汉大学,人民医院,副主任医师(2004),副教授（2005）,主任医师（2019） 2014.08-2017.08武汉大学,人民医院东院,综合二科主任 2017.09-至今武汉大学,人民医院东院,CCU主任兼东院心内科副主任 |
| 成果获奖 | 在2020年COVID-19疫情期间，我们团队利用“互联网+抗疫”的理念，与“全国心电医联体联盟”合作，通过阜外医院心电血压远程监控云平台，在东院多个感染病区搭建了武汉大学人民医院重症COVID-19患者的远程监控体系。被央视2频道经济半小时节目、人民网、长江日报等报道，我们的远程动态血压监测系统“康康盛世”也获得了人民网--人民战役内容科技大赛“医疗应用创新奖”，个人也荣获中华医学会心血管病分会 “抗疫英雄奖”，民进中央授予的抗击新冠肺炎“先进个人”和民进湖北省委授予的“抗疫先锋”称号。参编《图说病毒》获2021年湖北省科技进步二等奖（排名第三）。 |
| 代表性论著 |
（1)
Ganesh S(#), Zhong P, Zhou X(*). Cardiotoxicity induced by immune checkpoint
inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and
treatment. Front Cardiovasc Med. 2022 Sep 20;9:997660. (IF: 5.85) （2) Chen Y(#), Liu Y(#), Wang Y, Chen X, Wang C, Chen X, Yuan X, Liu L, Yang J(*), Zhou X(*). Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophages. J Exp Clin Cancer Res. 2022 Jan 3;41(1):1. (IF: 12.66) （3) Li S(#), Wang X(#), Hu H(#), Xu J, He J, Yang W, He B, Liu Y, Yu H, Zhou Q, Zhang H, Liu T, Hu K, Zhao Y, Huang Z, Zhu H, Zhang B, Zhao S, Sirajuddin A, Arai AE, Chen J, Zhou X(*)., Lu M(*).. Additional Value of Non-contrast Chest CT in the Prediction of Adverse Cardiovascular Events in Patients With Novel Coronavirus Disease 2019 (COVID-19). Front. Cardiovasc. Med., 2021 Oct 15；8:738044. (IF: 6.050) （4) He J(#), Zhang B(#), Zhou Q(#), Yang W, Xu J, Liu T, Zhang H, Wu Z, Li D, Zhou Q, Yan J, Zhang C, Qian H, Lu M(*),Zhou X(*). The prognostic value of myocardial injury in COVID-19 patients and associated characteristics. Immun Inflamm Dis. 2021 Dec;9(4):1358-1369. (IF: 2.239) （5) Zhang S(#), Zhou X(#), Chen Y, Wang L, Zhu B, Jiang Y, Bu P, Liu W, Li D, Li Y, Tao Y, Ren J, Fu L, Li Y, Shen X, Liu H, Sun G, Xu X, Bai J, Zhang W(*), Cai J(*); STEP Study Group. Changes in Home Blood Pressure Monitored Among Elderly Patients With Hypertension During the COVID-19 Outbreak: A Longitudinal Study in China Leveraging a Smartphone-Based Application. Circ Cardiovasc Qual Outcomes. 2021 May;14(5):e007098. (IF: 5.882) （6) Cai C, Liu FC, Li JX, Huang KY, Yang XL, Chen JC, Liu XQ, Cao J, Chen SF, Shen C, Yu L, Lu FH, Wu XP, Zhao LC, Li Y, Hu DS, Huang JF, Zhou XY(*), Lu XF(*), Gu DF. Effects of the total physical activity and its changes on incidence, progression, and remission of hypertension. J Geriatr Cardiol. 2021;18(3):175-184. (IF: 3.327) （7) Zhao J(#), Yang Y(#), Huang H(#), Li D(#), Gu D, Lu X, Zhang Z, Liu L, Liu T, Liu Y, He Y, Sun B, Wei M, Yang G, Wang X(*), Zhang L(*), Zhou X(*), Xing M(*), Wang PG(*). Relationship between the ABO Blood Group and the COVID-19 Susceptibility. Clin Infect Dis. 2021 Jul 15;73(2):328-331. (IF: 9.079) （8) Wu Z(*), Hu R, Zhang C, Ren W, Yu A, Zhou X(*). Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients. Critical Care, 2020; 24: 290. (IF: 9.097) （9) Zhang B(#), Zhou X(#), Qiu Y(#), Song Y(#), Feng F, Feng J, Song Q(*), Jia Q(*), Wang J(*). Clinical characteristics of 82 cases of death from COVID-19. PLOS ONE. 2020, 15(7): 1-13. (IF: 3.24) （10) Zhang B(#), Zhou X(#), Zhu C(#), Song Y(#), Feng F, Qiu Y, Feng J, Jia Q, Song Q(*), Zhu B(*), Wang J(*). Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19.Front. Mol. Biosci. 2020;7(157): 1-7. (IF: 5.246) （11) Liu Y, Duan C, Liu W, Chen X, Wang Y, Liu X, Yue J, Yang J, Zhou X(*). Upregulation of let-7f-2-3p by long noncoding RNA NEAT1 inhibits XPO1-mediated HAX-1 nuclear export in both in vitro and in vivo rodent models of doxorubicin-induced cardiotoxicity. Arch Toxicol. 2019;93(11):3261-3276.(IF:5.74) （12) Huang K, Liu Y, Tang H, Qiu M, Li C, Duan C, Wang C, Yang J, and Zhou X(*). Glabridin prevents Doxorubicin-induced cardiotoxicity through gut microbiota modulation and colonic macrophage polarization in mice. Front. Pharmacol. 2019.Feb.15;10:107 (IF: 5.81) （13) Liu Y, Tang H, Liu X, Chen H, Feng N, Zhang J, Wang C, Qiu M, Yang J, Zhou X(*). Frontline Science: Reprogramming COX-2, 5-LOX, and CYP4A-mediated arachidonic acid metabolism in macrophages by salidroside alleviates gouty arthritis.J Leukoc Biol. 2019;105(1):11-24 (IF: 4.962) （14) Chen G(#), Zhou X(#), Florea S, Qian J, Cai W, Zhang Z, Fan GC, Lorenz J, Hajjar RJ, Kranias EG. Expression of active protein phosphatase 1 inhibitor-1 attenuates chronic beta-agonist-induced cardiac apoptosis. Basic Res Cardiol. 2010 ;105:573-581 (IF: 17.165) （15) Chen G(#), Zhou X(#), Pathak A, Dorn GW, Kranias EG. The human G147D-protein phosphatase 1 inhibitor-1 polymorphism is not associated with altered clinical characteristics in heart failure. Cardiology. 2009;112:224-231 (IF: 1.869) （16) Zhou X, Fan GC, Ren X, Waggoner GR, Gregory KN, Chen G, Jones WK, Kranias EG(*). Overexpression of histidine-rich ca-binding protein protects against ischemia/reperfusion-induced cardiac injury. Cardiovascular Research. 2007; 75:487-497 (同期特别专家评论，IF: 10.787) （17) Zhao J(#), Zhou X(#), Huang J, Chen J, Gu D(*). Association study of the thrombomodulin -33G>A polymorphism with coronary artery disease and myocardial infarction in Chinese Han population. International Journal of Cardiology. 2005;100:383-388 (IF: 4.164) （18) Zhou X, Huang J, Chen J, Su S, Chen R, Gu D(*). Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study. Thrombosis and Haemostasis. 2004; 92:867-873 (IF: 5.249) （19) Zhou X, Huang J, Chen J, Zhao J, Yang W, Wang X, Gu D(*). Thrombospondin-4 A387P polymorphism is not associated with coronary artery disease and myocardial infarction in the Chinese Han population. Clinical Science. 2004; 106:495-500 (IF: 6.124) （20) Zhou X, Huang J, Chen J, Zhao J, Ge D, Yang W, Gu D(*). Genetic association analysis of myocardial infarction with thrombospondin-1 N700S variant in a Chinese population. Thrombosis Research. 2004; 113:181-186 (IF: 3.944) |
| Name | XIAOYANG ZHOU |
| Date of birth | Oct.，1968 |
| Department | Department of Cardiology, Renmin Hospital, Wuhan University. |
| Title | Associate Professor, doctoral tutor |
| xiaoyangzh@whu.edu.cn | |
| TEL | 027-88041911-89025 or 18986033792 |
| Research Direction | 1. Hypertension , 2. Cardiomyopathy and heart failure. |
| Personal Profile |
He is mainly engaged in the clinical diagnosis and treatment of cardiovascular diseases,and has been awarded 2 items form the National Natural Science Foundation, 1 items from the Provincial Health Department.Besides,there are more than 70 articles published in medical journals , including more than 50 SCI papers. and more than 20 papers published by the first author or corresponding author. |
| Selected Publications |
（1)
Ganesh S(#), Zhong P, Zhou X(*). Cardiotoxicity induced by immune checkpoint
inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and
treatment. Front Cardiovasc Med. 2022 Sep 20;9:997660. (IF: 5.85) （2) Chen Y(#), Liu Y(#), Wang Y, Chen X, Wang C, Chen X, Yuan X, Liu L, Yang J(*), Zhou X(*). Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophages. J Exp Clin Cancer Res. 2022 Jan 3;41(1):1. (IF: 12.66) （3) Li S(#), Wang X(#), Hu H(#), Xu J, He J, Yang W, He B, Liu Y, Yu H, Zhou Q, Zhang H, Liu T, Hu K, Zhao Y, Huang Z, Zhu H, Zhang B, Zhao S, Sirajuddin A, Arai AE, Chen J, Zhou X(*)., Lu M(*).. Additional Value of Non-contrast Chest CT in the Prediction of Adverse Cardiovascular Events in Patients With Novel Coronavirus Disease 2019 (COVID-19). Front. Cardiovasc. Med., 2021 Oct 15；8:738044. (IF: 6.050) （4) He J(#), Zhang B(#), Zhou Q(#), Yang W, Xu J, Liu T, Zhang H, Wu Z, Li D, Zhou Q, Yan J, Zhang C, Qian H, Lu M(*),Zhou X(*). The prognostic value of myocardial injury in COVID-19 patients and associated characteristics. Immun Inflamm Dis. 2021 Dec;9(4):1358-1369. (IF: 2.239) （5) Zhang S(#), Zhou X(#), Chen Y, Wang L, Zhu B, Jiang Y, Bu P, Liu W, Li D, Li Y, Tao Y, Ren J, Fu L, Li Y, Shen X, Liu H, Sun G, Xu X, Bai J, Zhang W(*), Cai J(*); STEP Study Group. Changes in Home Blood Pressure Monitored Among Elderly Patients With Hypertension During the COVID-19 Outbreak: A Longitudinal Study in China Leveraging a Smartphone-Based Application. Circ Cardiovasc Qual Outcomes. 2021 May;14(5):e007098. (IF: 5.882) （6) Cai C, Liu FC, Li JX, Huang KY, Yang XL, Chen JC, Liu XQ, Cao J, Chen SF, Shen C, Yu L, Lu FH, Wu XP, Zhao LC, Li Y, Hu DS, Huang JF, Zhou XY(*), Lu XF(*), Gu DF. Effects of the total physical activity and its changes on incidence, progression, and remission of hypertension. J Geriatr Cardiol. 2021;18(3):175-184. (IF: 3.327) （7) Zhao J(#), Yang Y(#), Huang H(#), Li D(#), Gu D, Lu X, Zhang Z, Liu L, Liu T, Liu Y, He Y, Sun B, Wei M, Yang G, Wang X(*), Zhang L(*), Zhou X(*), Xing M(*), Wang PG(*). Relationship between the ABO Blood Group and the COVID-19 Susceptibility. Clin Infect Dis. 2021 Jul 15;73(2):328-331. (IF: 9.079) （8) Wu Z(*), Hu R, Zhang C, Ren W, Yu A, Zhou X(*). Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients. Critical Care, 2020; 24: 290. (IF: 9.097) （9) Zhang B(#), Zhou X(#), Qiu Y(#), Song Y(#), Feng F, Feng J, Song Q(*), Jia Q(*), Wang J(*). Clinical characteristics of 82 cases of death from COVID-19. PLOS ONE. 2020, 15(7): 1-13. (IF: 3.24) （10) Zhang B(#), Zhou X(#), Zhu C(#), Song Y(#), Feng F, Qiu Y, Feng J, Jia Q, Song Q(*), Zhu B(*), Wang J(*). Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19.Front. Mol. Biosci. 2020;7(157): 1-7. (IF: 5.246) （11) Liu Y, Duan C, Liu W, Chen X, Wang Y, Liu X, Yue J, Yang J, Zhou X(*). Upregulation of let-7f-2-3p by long noncoding RNA NEAT1 inhibits XPO1-mediated HAX-1 nuclear export in both in vitro and in vivo rodent models of doxorubicin-induced cardiotoxicity. Arch Toxicol. 2019;93(11):3261-3276.(IF:5.74) （12) Huang K, Liu Y, Tang H, Qiu M, Li C, Duan C, Wang C, Yang J, and Zhou X(*). Glabridin prevents Doxorubicin-induced cardiotoxicity through gut microbiota modulation and colonic macrophage polarization in mice. Front. Pharmacol. 2019.Feb.15;10:107 (IF: 5.81) （13) Liu Y, Tang H, Liu X, Chen H, Feng N, Zhang J, Wang C, Qiu M, Yang J, Zhou X(*). Frontline Science: Reprogramming COX-2, 5-LOX, and CYP4A-mediated arachidonic acid metabolism in macrophages by salidroside alleviates gouty arthritis.J Leukoc Biol. 2019;105(1):11-24 (IF: 4.962) （14) Chen G(#), Zhou X(#), Florea S, Qian J, Cai W, Zhang Z, Fan GC, Lorenz J, Hajjar RJ, Kranias EG. Expression of active protein phosphatase 1 inhibitor-1 attenuates chronic beta-agonist-induced cardiac apoptosis. Basic Res Cardiol. 2010 ;105:573-581 (IF: 17.165) （15) Chen G(#), Zhou X(#), Pathak A, Dorn GW, Kranias EG. The human G147D-protein phosphatase 1 inhibitor-1 polymorphism is not associated with altered clinical characteristics in heart failure. Cardiology. 2009;112:224-231 (IF: 1.869) （16) Zhou X, Fan GC, Ren X, Waggoner GR, Gregory KN, Chen G, Jones WK, Kranias EG(*). Overexpression of histidine-rich ca-binding protein protects against ischemia/reperfusion-induced cardiac injury. Cardiovascular Research. 2007; 75:487-497 (同期特别专家评论，IF: 10.787) （17) Zhao J(#), Zhou X(#), Huang J, Chen J, Gu D(*). Association study of the thrombomodulin -33G>A polymorphism with coronary artery disease and myocardial infarction in Chinese Han population. International Journal of Cardiology. 2005;100:383-388 (IF: 4.164) （18) Zhou X, Huang J, Chen J, Su S, Chen R, Gu D(*). Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study. Thrombosis and Haemostasis. 2004; 92:867-873 (IF: 5.249) （19) Zhou X, Huang J, Chen J, Zhao J, Yang W, Wang X, Gu D(*). Thrombospondin-4 A387P polymorphism is not associated with coronary artery disease and myocardial infarction in the Chinese Han population. Clinical Science. 2004; 106:495-500 (IF: 6.124) （20) Zhou X, Huang J, Chen J, Zhao J, Ge D, Yang W, Gu D(*). Genetic association analysis of myocardial infarction with thrombospondin-1 N700S variant in a Chinese population. Thrombosis Research. 2004; 113:181-186 (IF: 3.944) |
武汉大学人民医院
湖北省人民医院